Leukemia - Table of Contents alert Volume 29 Issue 1

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 29, Issue 1 (January 2015) In this issue Reviews Original Articles Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Follow on Twitter Subscribe Reviews Top Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches A Rambaldi, E Biagi, C Bonini, A Biondi and M Introna Leukemia 2015 29: 1-10; advance online publication, June 12, 2014; 10.1038/leu.2014.189 Abstract | Full Text Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy OPEN B T Gjertsen and P Schöffski Leukemia 2015 29: 11-19; advance online publication, July 16, 2014; 10.1038/leu.2014.222 Abstract | Full Text Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) G Barosi, A Tefferi, C Besses, G Birgegard, F Cervantes, G Finazzi, H Gisslinger, M Griesshammer, C Harrison, R Hehlmann, S Hermouet, J-J Kiladjian, N Kröger, R Mesa, M F Mc Mullin, A Pardanani, F Passamonti, J Samuelsson, A M Vannucchi, A Reiter, R T Silver, S Verstovsek, G Tognoni and T Barbui Leukemia 2015 29: 20-26; advance online publication, 16 September 2014; 10.1038/leu.2014.250 Abstract | Full Text Original Articles Top MOLECULAR TARGETS FOR THERAPY Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies E Weisberg, A Nonami, Z Chen, F Liu, J Zhang, M Sattler, E Nelson, K Cowens, A L Christie, C Mitsiades, K-K Wong, Q Liu, N Gray and J D Griffin Leukemia 2015 29: 27-37; advance online publication, May 5, 2014; 10.1038/leu.2014.149 Abstract | Full Text ACUTE LEUKEMIAS Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement M Bardini, P S Woll, L Corral, S Luc, L Wittmann, Z Ma, L Lo Nigro, G Basso, A Biondi, G Cazzaniga and S E W Jacobsen Leukemia 2015 29: 38-50; advance online publication, May 6, 2014; 10.1038/leu.2014.154 Abstract | Full Text Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission J Versluis, M Labopin, D Niederwieser, G Socie, R F Schlenk, N Milpied, A Nagler, D Blaise, V Rocha, J J Cornelissen and M Mohty Leukemia 2015 29: 51-57; advance online publication, May 20, 2014; 10.1038/leu.2014.164 Abstract | Full Text Evolutionary trajectories of hyperdiploid ALL in monozygotic twins C M Bateman, D Alpar, A M Ford, S M Colman, D Wren, M Morgan, L Kearney and M Greaves Leukemia 2015 29: 58-65; advance online publication, June 4, 2014; 10.1038/leu.2014.177 Abstract | Full Text MYELODYSPLASIAS Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes M G Della Porta, E Travaglino, E Boveri, M Ponzoni, L Malcovati, E Papaemmanuil, G M Rigolin, C Pascutto, G Croci, U Gianelli, R Milani, I Ambaglio, C Elena, M Ubezio, M C Da Via’, E Bono, D Pietra, F Quaglia, R Bastia, V Ferretti, A Cuneo, E Morra, P J Campbell, A Orazi, R Invernizzi and M Cazzola on behalf of Rete Ematologica Lombarda (REL) clinical network Leukemia 2015 29: 66-75; advance online publication, May 20, 2014; 10.1038/leu.2014.161 Abstract | Full Text CHRONIC MYELOPROLIFERATIVE NEOPLASIAS Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia L Schafranek, E Nievergall, J A Powell, D K Hiwase, T Leclercq, T P Hughes and D L White Leukemia 2015 29: 76-85; advance online publication, May 12, 2014; 10.1038/leu.2014.156 Abstract | Full Text CHRONIC LYMPHOCYTIC LEUKEMIA Allele-specific loss and transcription of the miR-15a/16-1 cluster in chronic lymphocytic leukemia OPEN A Veronese, F Pepe, J Chiacchia, S Pagotto, P Lanuti, S Veschi, M Di Marco, A D'Argenio, I Innocenti, B Vannata, F Autore, M Marchisio, D Wernicke, F Verginelli, G Leone, L Z Rassenti, T J Kipps, R Mariani-Costantini, L Laurenti, C M Croce and R Visone Leukemia 2015 29: 86-95; advance online publication, April 15, 2014; 10.1038/leu.2014.139 Abstract | Full Text The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells M López-Guerra, S Xargay-Torrent, L Rosich, A Montraveta, J Roldán, A Matas-Céspedes, N Villamor, M Aymerich, C López-Otín, P Pérez-Galán, G Roué, E Campo and D Colomer Leukemia 2015 29: 96-106; advance online publication, April 30, 2014; 10.1038/leu.2014.143 Abstract | Full Text Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL O Middleton, E Cosimo, E Dobbin, A M McCaig, C Clarke, A M Brant, M T Leach, A M Michie and H Wheadon Leukemia 2015 29: 107-114; advance online publication, May 2, 2014; 10.1038/leu.2014.146 Abstract | Full Text Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation F Palacios, C Abreu, D Prieto, P Morande, S Ruiz, T Fernández-Calero, H Naya, G Libisch, C Robello, A I Landoni, R Gabus, G Dighiero and P Oppezzo Leukemia 2015 29: 115-125; advance online publication, May 14, 2014; 10.1038/leu.2014.158 Abstract | Full Text CYTOGENETICS AND MOLECULAR GENETICS PRPF8 defects cause missplicing in myeloid malignancies A Kurtovic-Kozaric, B Przychodzen, J Singh, M M Konarska, M J Clemente, Z K Otrock, M Nakashima, E D Hsi, K Yoshida, Y Shiraishi, K Chiba, H Tanaka, S Miyano, S Ogawa, J Boultwood, H Makishima, J P Maciejewski and R A Padgett Leukemia 2015 29: 126-136; advance online publication, April 30, 2014; 10.1038/leu.2014.144 Abstract | Full Text MINIMAL RESIDUAL DISEASE Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation R B Walter, B Gyurkocza, B E Storer, C D Godwin, J M Pagel, S A Buckley, M L Sorror, B L Wood, R Storb, F R Appelbaum and B M Sandmaier Leukemia 2015 29: 137-144; advance online publication, June 3, 2014; 10.1038/leu.2014.173 Abstract | Full Text IMMUNOLOGY Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking A Sato, C Nishida, K Sato-Kusubata, M Ishihara, Y Tashiro, I Gritli, H Shimazu, S Munakata, H Yagita, K Okumura, Y Tsuda, Y Okada, A Tojo, H Nakauchi, S Takahashi, B Heissig and K Hattori Leukemia 2015 29: 145-156; advance online publication, May 5, 2014; 10.1038/leu.2014.151 Abstract | Full Text Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling A Sharma, H Yun, N Jyotsana, A Chaturvedi, A Schwarzer, E Yung, C K Lai, F Kuchenbauer, B Argiropoulos, K Görlich, A Ganser, R K Humphries and M Heuser Leukemia 2015 29: 157-168; advance online publication, May 20, 2014; 10.1038/leu.2014.162 Abstract | Full Text SENSITIVITY AND RESISTANCE TO THERAPY The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia Y Cao, Z R Hunter, X Liu, L Xu, G Yang, J Chen, C J Patterson, N Tsakmaklis, S Kanan, S Rodig, J J Castillo and S P Treon Leukemia 2015 29: 169-176; advance online publication, June 10, 2014; 10.1038/leu.2014.187 Abstract | Full Text ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts A P A Theocharides, S M Dobson, E Laurenti, F Notta, V Voisin, P-Y Cheng, J S Yuan, C J Guidos, M D Minden, C G Mullighan, E Torlakovic and J E Dick Leukemia 2015 29: 177-187; advance online publication, May 5, 2014; 10.1038/leu.2014.150 Abstract | Full Text Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron V Visconte, N Avishai, R Mahfouz, A Tabarroki, J Cowen, R Sharghi-Moshtaghin, M Hitomi, H J Rogers, E Hasrouni, J Phillips, M A Sekeres, A H Heuer, Y Saunthararajah, J Barnard and R V Tiu Leukemia 2015 29: 188-195; advance online publication, May 23, 2014; 10.1038/leu.2014.170 Abstract | Full Text MYELOMA piRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma H Yan, Q-L Wu, C-Y Sun, L-S Ai, J Deng, L Zhang, L Chen, Z-B Chu, B Tang, K Wang, X-F Wu, J Xu and Y Hu Leukemia 2015 29: 196-206; advance online publication, April 15, 2014; 10.1038/leu.2014.135 Abstract | Full Text Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma M Hiasa, J Teramachi, A Oda, R Amachi, T Harada, S Nakamura, H Miki, S Fujii, K Kagawa, K Watanabe, I Endo, Y Kuroda, T Yoneda, D Tsuji, M Nakao, E Tanaka, K Hamada, S Sano, K Itoh, T Matsumoto and M Abe Leukemia 2015 29: 207-217; advance online publication, May 2, 2014; 10.1038/leu.2014.147 Abstract | Full Text A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients J Bae, R Prabhala, A Voskertchian, A Brown, C Maguire, P Richardson, G Dranoff, K C Anderson and N C Munshi Leukemia 2015 29: 218-229; advance online publication, May 14, 2014; 10.1038/leu.2014.159 Abstract | Full Text Letters to the Editor Top Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment D T Yeung, D J Moulton, S L Heatley, E Nievergall, P Dang, J Braley, S Branford, S Moore, C G Mullighan, T P Hughes and D L White Leukemia 2015 29: 230-232; advance online publication, September 2, 2014; 10.1038/leu.2014.256 Full Text Transient abnormal myelopoiesis/acute megakaryoblastic leukemia diagnosed in the placenta of a stillborn Down syndrome fetus with targeted next-generation sequencing B Federmann, A Fasan, K O Kagan, S Haen and F Fend Leukemia 2015 29: 232-233; advance online publication, September 2, 2014; 10.1038/leu.2014.258 Full Text The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice T R Rosean, V S Tompkins, A K Olivier, R Sompallae, L A Norian, H C Morse, III, T J Waldschmidt and S Janz Leukemia 2015 29: 233-237; advance online publication, September 3, 2014; 10.1038/leu.2014.260 Full Text Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis OPEN J H Schatz, S M Horwitz, J Teruya-Feldstein, M A Lunning, A Viale, K Huberman, N D Socci, N Lailler, A Heguy, I Dolgalev, J C Migliacci, M Pirun, M L Palomba, D M Weinstock and H-G Wendel Leukemia 2015 29: 237-241; advance online publication, September 26, 2014; 10.1038/leu.2014.261 Full Text The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading O Pozdnyakova, S Rodig, S Bhandarkar, K Wu, J Thiele and R Hasserjian Leukemia 2015 29: 241-244; advance online publication, September 3, 2014; 10.1038/leu.2014.262 Full Text In vitro induction of antibody secretion of primary B-cell chronic lymphocytic leukaemia cells R Hoogeboom, R J A Reinten, J-J Schot, J E J Guikema, R J Bende and C J M van Noesel Leukemia 2015 29: 244-247; advance online publication, September 10, 2014; 10.1038/leu.2014.266 Full Text Value of routine ‘day 14’ marrow exam in newly diagnosed AML T Yezefski, H Xie, R Walter, J Pagel, P S Becker, P Hendrie, V Sandhu, K Shannon-Dorcy, J Abkowitz, F R Appelbaum and E Estey Leukemia 2015 29: 247-249; advance online publication, September 10, 2014; 10.1038/leu.2014.268 Full Text Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution X Cabagnols, J P Defour, V Ugo, J C Ianotto, P Mossuz, J Mondet, F Girodon, J H Alexandre, O Mansier, J F Viallard, E Lippert, A Murati, M J Mozziconacci, P Saussoy, M C Vekemans, L Knoops, F Pasquier, V Ribrag, E Solary, I Plo, S N Constantinescu, N Casadevall, W Vainchenker, C Marzac and O Bluteau Leukemia 2015 29: 249-252; advance online publication, September 19, 2014; 10.1038/leu.2014.270 Full Text SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation OPEN S Bartels, U Lehmann, G Büsche, J Schlue, M Mozer, J Stadler, I Triviai, H Alchalby, N Kröger and H Kreipe Leukemia 2015 29: 253-255; advance online publication, September 18, 2014; 10.1038/leu.2014.277 Full Text Protein kinase N3 deficiency impedes PI3-kinase pathway-driven leukemogenesis without affecting normal hematopoiesis M Kraus, B Dolinski, T W Rosahl and J A Magee Leukemia 2015 29: 255-258; advance online publication, September 19, 2014; 10.1038/leu.2014.278 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.